UTHR on XNAS, Health Care, United Therapeutics Corp, job postings
Measures activity, not value. Not investment advice.
Insiders sold $348.3M in 90 days with no purchases, while the stock rose 17% in a year.
BadNet income fell 3.2% to $1.2B over the last 12 months
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $832.5M, net income $258.6M.
31 Dec 2021RevenueNet incometallest bar $832.5M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$832.5M
$258.6M
30 Jun 2026
$783.3M
$333.0M
31 Mar 2026
$781.5M
$274.9M
31 Dec 2025
$790.2M
$364.3M
30 Sep 2025
$799.5M
$338.7M
30 Jun 2025
$798.6M
$309.5M
31 Mar 2025
$794.4M
$322.2M
31 Dec 2024
$735.9M
$301.3M
30 Sep 2024
$748.9M
$309.1M
30 Jun 2024
$714.9M
$278.1M
31 Mar 2024
$677.7M
$306.6M
31 Dec 2023
$614.7M
$217.1M
30 Sep 2023
$609.4M
$267.6M
30 Jun 2023
$596.5M
$259.2M
31 Mar 2023
$506.9M
$240.9M
31 Dec 2022
$491.5M
–
30 Sep 2022
$516.0M
$239.3M
30 Jun 2022
$466.9M
$116.0M
31 Mar 2022
$461.9M
$239.9M
31 Dec 2021
$415.2M
–
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$3.2B
$3.1B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+1.9%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.2B
$1.3B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$26.49
$26.41
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
86.3%
88.6%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
41.4%
47.7%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
38.6%
40.7%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
19.1%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$867.2M
$1.1B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$2.1B
$2.8B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$147.36
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
19.2
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
7.4
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
3.8
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$348.3M
bought $0, sold $348.3M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-2.2%
839 13F filers vs 858
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
42.7M shares held by 13F filers (30 Sep 2026) of 42.6M outstanding (28 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
4.3%
1.8M shares sold short (30 Oct 2026) of 42.6M outstanding (28 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.5
1.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-25%
2.5M shares sold short in the report before, 1.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
60%
60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+50%
15 vs 10 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+4.1%
$832.5M vs $799.5M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-14%
$180.7M vs $210.5M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$1.3M
the 12 months before: $610K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$300K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
39
39 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.8×
39 articles in the last 7 days; its usual week has 5.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 3.6M, 1.6× a year earlier
Price $554.73 on 20 Nov 2026, +17% over 12 months (12-month range $464.93 to $608.49)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $1.4B in the last 12 months (the 12 months before: -$422.8M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 15 published in the last 12 months, +50% on the 12 months before.Revenue per quarter. Revenue $832.5M in the latest quarter, +4.1% on a year earlier.Capital spending per quarter. Capital spending $180.7M in the latest quarter, -14% on a year earlier.Institutional holders (13F filers). 839 13F filers reported holding it in the latest 13F quarter, +26% on a year earlier.Federal obligations. Federal obligations: $752K published in the last 12 months, -7.8% on the 12 months before.Lobbying spend. Lobbying spend: $300K published in the last 12 months, +1400% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Reported lobbying spend: $80K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Sep 2025
New
Tiber Creek Groupfor United Therapeutics Corporation
Issues related to pharmaceuticals and organ transplantation.Health issues
Two or more unrelated kinds of records unusual within 30 days
19 Apr 2026confirmed
Confirmed across sources Lobbying and Short interest and volume
United Therapeutics(UTHR): had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 18 days.
Short interest and volume: Short interest spike, became public on 25 Mar 2026
Short interest and volume: Short interest spike, became public on 11 Apr 2026
Lobbying: Lobbying on a new issue, became public on 19 Apr 2026
The 13 Mar 2026 report against the 24 reports before it.
this reportearliernormal: 1.8MSee the evidence (3 changes)
Short interest and volume: Short interest spike became public on 25 Mar 2026
United Therapeutics had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.
This period
2.8M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
158K
How far from its usual level
+4.4
Same report last year
1.8M
History used
2,996 days
the 13 Mar 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
United Therapeutics had 2.8M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.
This period
2.8M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
176K
How far from its usual level
+4.0
Same report last year
1.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Lobbying: Lobbying on a new issue became public on 19 Apr 2026
United Therapeutics lobbying on a new issue.
New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687398
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
10 Oct 2026Short interest and volume change
had 3.6M shares sold short in the 30 Sep 2026 report, 1.6× the same report last year.
Same report last year: 2.2M; its normal report is 2.1M.
See the evidence
This period
3.6M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
260K
How far from its usual level
+3.9
Same report last year
2.2M
History used
3,197 days
the 30 Sep 2026 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 18 days.
See the evidence (3 changes)
Short interest and volume: Short interest spike became public on 25 Mar 2026
United Therapeutics had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.
This period
2.8M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
158K
How far from its usual level
+4.4
Same report last year
1.8M
History used
2,996 days
the 13 Mar 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
United Therapeutics had 2.8M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.
This period
2.8M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
176K
How far from its usual level
+4.0
Same report last year
1.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Lobbying: Lobbying on a new issue became public on 19 Apr 2026
United Therapeutics lobbying on a new issue.
New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687398
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
19 Apr 2026Lobbying change
lobbying on a new issue.
See the evidence
New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687398
11 Apr 2026Short interest and volume change
had 2.8M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.
Same report last year: 1.7M; its normal report is 1.8M.
See the evidence
This period
2.8M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
176K
How far from its usual level
+4.0
Same report last year
1.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.8M shares sold short in the 13 Mar 2026 report, 1.6× the same report last year.
Same report last year: 1.8M; its normal report is 1.8M.
See the evidence
This period
2.8M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
158K
How far from its usual level
+4.4
Same report last year
1.8M
History used
2,996 days
the 13 Mar 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $172.9M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.
Same quarter last year: $86.7M; its normal quarter is $75.7M.
See the evidence
This period
$172.9M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$75.7M
Typical spread (median absolute deviation)
$12.2M
How far from its usual level
+5.4
Same quarter last year
$86.7M
History used
3,562 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $75.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4689614
30 Oct 2025Financials change
spent $210.5M on capital projects in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.
Same quarter last year: $76.5M; its normal quarter is $70.3M.
See the evidence
This period
$210.5M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$70.3M
Typical spread (median absolute deviation)
$8.2M
How far from its usual level
+11.5
Same quarter last year
$76.5M
History used
3,470 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $70.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 4.1M shares sold short in the 30 Aug 2024 report, 3.7× the same report last year.
Same report last year: 1.1M; its normal report is 1.2M.
See the evidence
This period
4.1M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
243K
How far from its usual level
+7.9
Same report last year
1.1M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.1M shares sold short in the 15 Aug 2024 report, 2.2× the same report last year.
Same report last year: 1.9M; its normal report is 1.2M.
See the evidence
This period
4.1M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
243K
How far from its usual level
+8.1
Same report last year
1.9M
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.1M shares sold short in the 31 Jul 2024 report, 4.2× the same report last year.
Same report last year: 971K; its normal report is 1.2M.
See the evidence
This period
4.1M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
174K
How far from its usual level
+11.4
Same report last year
971K
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.2M shares sold short in the 15 Jul 2024 report, 4.2× the same report last year.
Same report last year: 993K; its normal report is 1.2M.
See the evidence
This period
4.2M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
152K
How far from its usual level
+13.3
Same report last year
993K
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 28 Jun 2024 report, 4.1× the same report last year.
Same report last year: 1.1M; its normal report is 1.1M.
See the evidence
This period
4.4M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
134K
How far from its usual level
+16.4
Same report last year
1.1M
History used
2,373 days
the 28 Jun 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 14 Jun 2024 report, 3.8× the same report last year.
Same report last year: 1.1M; its normal report is 1.1M.
See the evidence
This period
4.4M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
106K
How far from its usual level
+20.5
Same report last year
1.1M
History used
2,359 days
the 14 Jun 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 31 May 2024 report, 3.7× the same report last year.
Same report last year: 1.0M; its normal report is 1.1M.
See the evidence
This period
3.9M (the 31 May 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
98K
How far from its usual level
+18.9
Same report last year
1.0M
History used
2,345 days
the 31 May 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.8M shares sold short in the 15 May 2024 report, 2.8× the same report last year.
Same report last year: 1.3M; its normal report is 1.1M.
See the evidence
This period
3.8M (the 15 May 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
98K
How far from its usual level
+18.1
Same report last year
1.3M
History used
2,329 days
the 15 May 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 30 Apr 2024 report, 2.6× the same report last year.
Same report last year: 1.5M; its normal report is 1.1M.
See the evidence
This period
3.9M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
98K
How far from its usual level
+18.7
Same report last year
1.5M
History used
2,314 days
the 30 Apr 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.3M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.
Same report last year: 1.4M; its normal report is 1.1M.
See the evidence
This period
4.3M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
98K
How far from its usual level
+21.9
Same report last year
1.4M
History used
2,299 days
the 15 Apr 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.9M shares sold short in the 28 Mar 2024 report, 3.4× the same report last year.
Same report last year: 1.4M; its normal report is 1.1M.
See the evidence
This period
4.9M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
98K
How far from its usual level
+25.8
Same report last year
1.4M
History used
2,281 days
the 28 Mar 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 15 Mar 2024 report, 1.4× the same report last year.
Same report last year: 1.3M; its normal report is 1.1M.
See the evidence
This period
1.9M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
98K
How far from its usual level
+5.4
Same report last year
1.3M
History used
2,268 days
the 15 Mar 2024 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year.
Same report last year: 1.1M; its normal report is 1.3M.
See the evidence
This period
1.9M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
85K
How far from its usual level
+4.2
Same report last year
1.1M
History used
2,055 days
the 15 Aug 2023 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $68.8M on capital projects in the quarter ended 30 Sep 2022, 3.0× the same quarter last year.
Same quarter last year: $23.3M; its normal quarter is $16.1M.
See the evidence
This period
$68.8M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$16.1M
Typical spread (median absolute deviation)
$3.1M
How far from its usual level
+11.3
Same quarter last year
$23.3M
History used
4,748 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $16.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.
Not listed: 1020 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001082554
Ticker
UTHR
Domain
unither.com
Employer name
UNITED THERAPEUTICS (1 unverified)
Hq location
MD|SILVER SPRING|20910 (1 unverified)
Lobbying client
united therapeutics
Name
1109 Spring Managing Holdings, LLC, a Delaware limited liability company, 1109 Spring Managing Member, LLC, a Delaware limited liability company, 1111 Spring Holdings, LLC, a Delaware limited liability company, Document and 18 more
Uei
KK5FBFA43JS7
Wikipedia
United Therapeutics
DOL H-1B labor condition applications and PERM certifications250 data points14 Oct 2019 to 21 Sep 2026
Federal lobbying disclosures (LDA)3 records, 36 data points26 Sep 2008 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)185 records19 Jan 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1230 data points31 Dec 2007 to 28 Oct 2026
SEC Form 4 insider transactions859 records, 2728 data points7 Jan 2016 to 19 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards2832 data points14 Nov 2007 to 18 Sep 2026
Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026